Compare Ecopetrol SA (EC) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Enveric Biosciences Inc — how do they compare? Ecopetrol SA trades at $16.91 (market cap $33.11B), while Enveric Biosciences Inc trades at $1.48 (market cap $6.80M). The key difference: Ecopetrol SA is far larger — about 4869.1× Enveric Biosciences Inc's market cap, and Ecopetrol SA pays a 3.83% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Enveric Biosciences Inc for 14 Days on average.
| EC | ENVB | |
|---|---|---|
Market Cap | $33.11B | $6.80M |
Volume | 993,598 | 64,867 |
Sector | Energy | Health |
52-Week High | $18.26 | $10.80 |
52-Week Low | $8.61 | $1.27 |
Typical Hold Time | 84 Days | 14 Days |
Enterprise Value | $61.36B | -$1.49M |
Dividend Yield | 3.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $17.07, up 2.65% on the day, but faces a bearish technical signal with recent earnings misses. Revenue declined to $119.69T in 2025, with net income margin at 8.76%, though profitability metrics like ROE (17.67%) remain solid. The company is undergoing senior management changes amid government-led board restructuring, creating uncertainty.
The outlook is mixed: low valuations (P/E 7.97, EV/EBITDA 4) suggest potential upside, but declining revenue, earnings volatility, and political interference pose significant risks. Analyst consensus is cautious with a $16.85 price target below current levels, indicating limited near-term catalysts for substantial growth.
ENVB trades at $1.48, down 1.0% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -235.48% and ROA at -193.53%, though it has beaten EPS expectations for four consecutive quarters. Recent developments include patent allowances for non-hallucinogenic therapeutics and positive preclinical data for EB-003.
While analyst consensus is 75% buy with no sell ratings, fundamental weaknesses in revenue generation and negative cash flow from operations pose significant risks. The stock's appeal hinges on clinical progress and regulatory milestones, making it suitable for risk-tolerant investors betting on biotech innovation amid high operational and financial volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
